The performance of screening for PE by the Bayes’ theorem‐based method was compared with that of the NICE method
Detection rate (DR) using NICE method vs mini‐combined test (maternal factors, MAP and PAPP‐A) in the prediction of PE at any gestational age (all‐PE) for the same screen‐positive rate determined by the NICE method
DR of screening recommended by the NICE guidelines vs 3 Bayes’ theorem‐based methods for prediction of preterm PE (requiring delivery <37weeks)
Maternal factors, MAP and PAPP‐A
Maternal factors, MAP and PlGF
Maternal factors, MAP, UtA‐PI and PlGF
17,051 women were eligible and outcome data were obtained from 16,747
All-PE developed in 2.8% of the 16,747 pregnancies and preterm PE developed in 0.8%
NICE method for PE
Screen positive rate: 10.3%
DR for all‐PE: 30.4%
DR for preterm PE: 40.8%
There was only 23% compliance with aspirin recommendation
Mini-combined method for PE
DR of the mini‐combined test for all‐PE was 42.5%
Superior to that of the NICE method by 12.1% (95% CI, 7.9–16.2%)
Screening for preterm PE compared to NICE
Maternal factors, MAP and PlGF: DR was 69.0%, which was superior to NICE method by 28.2% (95% CI, 19.4–37.0%)
Maternal factors, MAP, UtA‐PI and PlGF: DR was 82.4%, which was to NICE method by 41.6% (95% CI, 33.2–49.9%)
NICE detection rates and compliance were lower than using a Bayesian approach that incorporates serum markers
The authors state that a PE methodology that combines biomarkers with maternal factors is a substantial improvement over current recommendations
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan